Cited by 640Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement DisordersNuclear Receptors and Signaling

The DOI matches its Crossref record; 238 of the 240 references it cites were found in a registry or an index.

Epidemiology of parkinson’s disease

Open access

Tanner, Caroline M., Goldman, Samuel M.·1996·Neurologic Clinics

DOI 10.1016/s0733-8619(05)70259-0PMC PMC7173037

Open this paper in CoChat — free account

Abstract

The epidemiologic studies reviewed here have provided insights into the etiology of PD. Evidence increasingly suggests that, like many other chronic age-related diseases, PD is a multifactorial disorder, with both genes and environment contributing to risk. As the elderly population of the world grows, incidence and prevalence of PD will continue to increase, underscoring the importance of further delineating risk factors. The introduction of levodopa and other pharmacologic therapies over the last 2 decades has postponed disease morbidity and mortality, but morbidity and mortality still are increased markedly relative to unaffected individuals. The development of therapies that may slow disease progression makes early identification and treatment of PD particularly important. Investigations of early markers of PD, or markers of disease susceptibility, are critical areas for future research. These efforts all will be aided by careful collaboration between epidemiologists and laboratory scientists.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0733-8619(05)70259-0

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
An Essay on the Shaking Palsy
Parkinson, J. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.2.223 · Cited by 2,856
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650
Case-Control Studies: Design, Conduct, Analysis.
Youkeles, L., & Schlesselman, J. J. (1983) · Journal of the American Statistical Association · doi:10.2307/2288156 · Cited by 2,358
Vitamin E Consumption and the Risk of Coronary Heart Disease in Men
Rimm, E. B., Stampfer, M. J., Ascherio, A., Giovannucci, E. L., Colditz, G. A., & Willett, W. C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282004 · Cited by 2,345
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Oxygen radicals and human disease
CROSS, C. E., HALLIWELL, B., BORISH, E. T., PRYOR, W. A., AMES, B. N., SAUL, R. L., McCORD, J. M., & HARMAN, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-526 · Cited by 1,856
Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects
Nehlig, A., Daval, J., & Debry, G. (1992) · Brain Research Reviews · doi:10.1016/0165-0173(92)90012-b · Cited by 1,463

Show all 240 references

Research works printed but not linked: 13

Breteler, 1995, Risk factors for Parkinson's disease: A population-based case-control study, Neurology, 45, A214
Campanella, 1990, Etiology of Parkinson's disease: Results of two case-control studies, Mov Disord, 5, 31
Davanipour, 1990, Residential histories in Parkinson's disease patients, Ann Neurol, 28, 295
Goetz, 1990, Motor vehicle accident and Parkinson's disease disability, Mov Disord, 5, 16
Kurth, 1995, Lack of association of CYP2D6 and MAO-B alleles with Parkinson's disease in a Kansas cohort, Neurology, 45, A429
Mjones, 1949, Paralysis agitans: A clinical and genetic study, Acta Psychiatry and Neurology, 54, 1
Rocca, 1990, Prevalence of Parkinson's disease and other parkinsonisms: A door-to-door survey in two Sicilian communities, Neurology, 40, 422
Tanner, 1989, Dietary antioxidant vitamins and the risk of developing Parkinson's disease, Neurology, 39, 181
Tanner, 1988, Vitamin use and Parkinson's disease, Ann Neurol, 233, 182
Treves, 1990, Case-control study, with use of temporal approach, for evaluation of risk factors for Parkinson's disease, Mov Disord, 5, 11
Uitti, 1991, Parkinsonism survival in the Levodopa era, Neurology, 41, 190
Vierregge, 1991, Parkinson's disease in twins, Neurology, 41, 255
Zimmerman, 1991, Parkinson's disease in monozygotic twins: A followup, Neurology, 41, 255

Sorted by citations

Items 301–400 of 640

Impairment of neuronal mitochondrial function by l-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage
Hörmann, P., Delcambre, S., Hanke, J. E., Geffers, R., Leist, M., & Hiller, K. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00547-4 · Cited by 35
Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration
Rite, I., Argüelles, S., Venero, J. L., García‐Rodríguez, S., Ayala, A., Cano, J., & Machado, A. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21452 · Cited by 28
Agrochemicals, α-Synuclein, and Parkinson’s Disease
Silva, B. A., Breydo, L., Fink, A. L., & Uversky, V. N. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8333-2 · Cited by 28
Prevalence of Parkinson's Disease in Hokkaido, the Northernmost Island of Japan.
Moriwaka, F., Tashiro, K., Kazunori, I. T. O. H., Honma, S., Okumura, H., Kikuchi, S., Hamada, T., Kaneko, S., & Kurokawa, Y. (1996) · Internal Medicine · doi:10.2169/internalmedicine.35.276 · Cited by 28
Prevalencia de las enfermedades neurológicas en el Valle del Cauca.Estudio Neuroepidemiológico Nacional (EPINEURO).
Takeuchi, Y., & Guevara, J. G. (1999) · Colombia medica · doi:10.25100/cm.v30i.2.126 · Cited by 28
Magnetic Resonance Imaging (MRI) in Parkinson′s Disease
Tuite, P. (2013) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.s1-001 · Cited by 27
Association Between Serum Zinc Levels and the Risk of Parkinson’s Disease: a Meta-Analysis
Sun, H., Liu, X., Ge, H., Wang, T., Wang, Y., & Li, W. (2017) · Biological Trace Element Research · doi:10.1007/s12011-017-0941-2 · Cited by 27
Pramipexole v. Levodopa as Initial Treatment for Parkinson’s Disease: A Randomized Clinical-Economic Trial
Noyes, K., Dick, A. W., Holloway, R. G., & Parkinson Study Group (2004) · Medical Decision Making · doi:10.1177/0272989x04268960 · Cited by 27
Neurodegenerative Diseases: New Hopes and Perspectives
Bhat, M. A., & Dhaneshwar, S. S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230907093451 · Cited by 29
A preliminary study of Parkinson’s gene therapy via sono-magnetic sensing gene vector for conquering extra/intracellular barriers in mice
Wu, C.-Y., Huang, R.-Y., Liao, E., Lin, Y., Ho, Y.-J., Chang, C., Chan, H., Huang, Y., Hsieh, T.-H., Fan, C., et al. (2020) · Brain stimulation · doi:10.1016/j.brs.2020.02.024 · Cited by 26
Conjugal Parkinsonism and Parkinson disease: A case series with environmental risk factor analysis
Willis, A. W., Sterling, C., & Racette, B. A. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.09.002 · Cited by 26
Risk of Parkinson disease after organophosphate or carbamate poisoning
Chuang, C., Su, H.-L., Lin, C., & Kao, C. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12707 · Cited by 26
Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study.
Mridula, K. R., Borgohain, R., Jabeen, S. A., Gaddamanugu, P., Bandaru, V. S., Ankathi, P., Kanikannan, M. A., & Khan, M. S. A. (2015) · PubMed Central · Cited by 26
Prevalence of tremor and Parkinson's disease
Khatter, A. S., Kurth, M., Brewer, M. A., Crinnian, C. T., Drazkowski, J. F., Flitman, S. S., Imke, S., Spector, S. A., Wood, K. L., & Lieberman, A. N. (1996) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(96)00027-2 · Cited by 26
ß-Carboline Analogues of MPP+ as Environmental Neurotoxins
Collins, M. A., & Neafsey, E. J. (2000) · Springer eBooks · doi:10.1007/978-1-4615-1269-1_13 · Cited by 26
The pragmatic use of apomorphine at the end of life
Dewhurst, F., Lee, M., & Wood, B. (2009) · Palliative Medicine · doi:10.1177/0269216309106979 · Cited by 25
Targeting the Chameleon: a Focused Look at α-Synuclein and Its Roles in Neurodegeneration
Silva, B. A., Breydo, L., & Uversky, V. N. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8334-1 · Cited by 25
Key Issues in Essential Tremor Genetics Research: Where Are We Now and How Can We Move Forward?
Testa, C. M. (2012) · Europe PMC (PubMed Central) · doi:10.7916/d8q23z0z · Cited by 26
Biopsychosocial Predictors of Depressive Mood in People With Parkinson's Disease
Moore, K., & Seeney, F. (2007) · Behavioral Medicine · doi:10.3200/bmed.33.1.29-38 · Cited by 25
Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
Hirsch, É. C., Hunot, S., Faucheux, B. A., Agid, Y., Mizuno, Y., Mochizuki, H., Tatton, W. G., Tatton, N. A., & Olanow, W. C. (1999) · Movement Disorders · doi:10.1002/1531-8257(199903)14:2 · Cited by 152
Automatic classification of the severity level of Parkinson's disease: a comparison of speaking tasks, features, and classifiers
Kodali, M., Kadiri, S. R., & Alku, P. (2024) · Computer Speech & Language · doi:10.1016/j.csl.2023.101548 · Cited by 24
Understanding the Modulation of α-Synuclein Fibrillation by N-Acetyl Aspartate: A Brain Metabolite
Khan, T., Waseem, R., Shahid, M., Ansari, J., Hassan, M. I., Shamsi, A., & Islam, A. (2024) · ACS Omega · doi:10.1021/acsomega.4c00595 · Cited by 24
In vivo protein targets for increased quinoprotein adduct formation in aged substantia nigra
Yu, G., Liu, H., Zhou, W. P., Zhu, X., Yu, C. Y., Wang, N., Zhang, Y., Ma, J., Zhao, Y., Xu, Y., et al. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.04.019 · Cited by 26
S100B polymorphisms are associated with age of onset of Parkinson’s disease
Fardell, C., Zettergren, A., Ran, C., Belin, A. C., Ekman, A., Sydow, O., Bäckman, L., Holmberg, B., Dizdar, N., Söderkvist, P., et al. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0547-3 · Cited by 24
Hepatotoxic profile of catechol-O-methyltranferase inhibitors in Parkinson?s disease
Benabou, R., & Waters, C. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.3.263 · Cited by 24
N-acetyltransferase-2 polymorphism in Parkinson's disease: the Rotterdam study
Harhangi, B. S., Oostra, B. A., Heutink, P., van Duijn, C. M., Albert Hofman, D., & Breteler, M. M. B. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.4.518 · Cited by 24
Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson Disease
Kitada, T., Tomlinson, J. J., Ao, H. S., Grimes, D. A., & Schlossmacher, M. G. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0175-8 · Cited by 23
“These authors also proposed a unique staging model for the development of idiopathic PD, and placed evidence of early SNCA misprocessing near the interface (s) of host and environment, specifically at the level of neurons in the digestive tract and the olfactory system [10], which conceptually is in agreement with a p…”
Background
Metabolic Analysis of Striatal Tissues from Parkinson’s Disease-like Rats by Electrospray Ionization Ion Mobility Mass Spectrometry
Zhang, X., Chiu, V. M., Stoica, G., Lungu, G. F., Schenk, J. O., & Hill, H. H. (2014) · Analytical Chemistry · doi:10.1021/ac4040967 · Cited by 23
Palliative care for patients with Parkinson’s disease: study protocol for a mixed methods study
Lennaerts, H. H., Groot, M. M., Steppe, M., van der Steen, J. T., den Brand, M. V., van Amelsvoort, D., Vissers, K. C. P., Munneke, M., & Bloem, B. R. (2017) · BMC Palliative Care · doi:10.1186/s12904-017-0248-2 · Cited by 23
The Role of a Neuropsychologist on a Movement Disorders Deep Brain Stimulation Team
Kubu, C. S. (2017) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx130 · Cited by 23
Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach
Padmakumar, S., Jones, G., Khorkova, O., Hsiao, J. H., Kim, J., Bleier, B. S., & Amiji, M. M. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120989 · Cited by 23
Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease
Mao, P., Meshul, C. K., Thuillier, P., & Reddy, P. (2013) · Pharmaceuticals · doi:10.3390/ph6010108 · Cited by 23
DJ-1 can inhibit microtubule associated protein 1 B formed aggregates
Wang, Z., Zhang, Y., Shi, Z., Guo, Q., Tan, Y., Wang, X., Xiong, R., Ding, J., & Chen, S. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-38 · Cited by 23
Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease
Swerdlow, R. H., Weaver, B., Grawey, A. E., Wenger, C., Freed, E., & Worrall, B. B. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.05.053 · Cited by 23
Overview of the neurotoxic effects in solvent-exposed workers
Viaene, M. K. (2002) · Cited by 23
A kindred with Parkinson’s disease not showing genetic linkage to established loci
Gwinn, K. A., Crook, R., Lincoln, S. J., Adler, C. H., Caviness, J. N., Hardy, J., & Farrer, M. J. (2000) · Neurology · doi:10.1212/wnl.54.2.504 · Cited by 23
In-Hospital Complications and Resource Utilization Following Lumbar Spine Surgery in Patients with Parkinson Disease: Evaluation of the National Inpatient Sample Database
Baker, J. F., McClelland, S., Line, B. G., Smith, J. S., Hart, R. A., Ames, C. P., Shaffrey, C. I., & Bess, S. R. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.07.006 · Cited by 22
Implications of enzyme deficiencies on mitochondrial energy metabolism and reactive oxygen species formation of neurons involved in rotenone‐induced Parkinson's disease: a model‐based analysis
Berndt, N., Holzhütter, H., & Bulik, S. (2013) · FEBS Journal · doi:10.1111/febs.12480 · Cited by 22
Pesticides and Parkinson's Disease: Current Experimental and Epidemiological Evidence
Goldman, S. M., Musgrove, R. E., Jewell, S. A., & Monte, D. A. D. (2017) · Advances in neurotoxicology · doi:10.1016/bs.ant.2017.07.004 · Cited by 21
Self-citation
Environmental and Genetic Variables Influencing Mitochondrial Health and Parkinson’s Disease Penetrance
Zanon, A., Pramstaller, P. P., Hicks, A. A., & Pichler, I. (2018) · Parkinson s Disease · doi:10.1155/2018/8684906 · Cited by 21
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson’s Disease Patients? A Systematic Review
Katsaiti, I., & Nixon, J. V. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-171225 · Cited by 22
Integrative Metabolomic and Metallomic Analysis in a Case–Control Cohort With Parkinson’s Disease
Lucio, M., Willkommen, D., Schroeter, M., Sigaroudi, A., Schmitt‐Kopplin, P., & Michalke, B. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00331 · Cited by 21
“As the world population ages, the total amount of people affected by PD is increasing (Tanner and Goldman, 1996).”
Background
Germline PTEN mutation in a family with Cowden syndrome and Bannayan‐Riley‐Ruvalcaba Syndrome
Zori, R. T., Marsh, D. J., Graham, G. E., Marliss, E. B., & Eng, C. (1998) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19981204)80:4 · Cited by 111
Spinal schistosomiasis
Gellido, C. L., Onesti, S., Llena, J. F., & Suarez, M. (2000) · Neurology · doi:10.1212/wnl.54.2.527 · Cited by 22
Cross-Sectional Study of the Prevalence of Parkinson’s Disease in the Kibbutz Movement in Israel
Anca‐Herschkovitsch, M., Paleacu, D., Shabtai, H., & Giladi, N. (2001) · Neuroepidemiology · doi:10.1159/000048614 · Cited by 22
Whole-brain dynamical modelling for classification of Parkinson’s disease
Jung, K., Florin, E., Patil, K. R., Caspers, J., Rubbert, C., Eickhoff, S. B., & Popovych, O. V. (2022) · Brain Communications · doi:10.1093/braincomms/fcac331 · Cited by 21
Amelioration of olfactory dysfunction in a mouse model of Parkinson’s disease via enhancing GABAergic signaling
Liu, X., Wang, K., Deng, X., Wei, Y., Guo, R., Liu, S.-F., Zhu, Y., Zhong, J.-J., Zheng, J.-Y., Wang, M., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01049-9 · Cited by 21
Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson’s patients leukocytes
Soreq, L., Bergman, H., Israel, Z. H., & Soreq, H. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-478 · Cited by 21
Pilot Study of Prevalence of Parkinson’s Disease in Australia
Chan, D. K. Y., Dunne, M. P., Wong, A., Hu, E., Hung, W. T., & Beran, R. G. (2001) · Neuroepidemiology · doi:10.1159/000054769 · Cited by 21
The Interrelated Multifactorial Actions of Cortisol and Klotho: Potential Implications in the Pathogenesis of Parkinson’s Disease
Luthra, N. S., Clow, A., & Corcos, D. M. (2022) · Brain Sciences · doi:10.3390/brainsci12121695 · Cited by 20
“Aging is the most critical risk factor for PD [7,76], yet the relationship between molecular/cellular processes of healthy aging and those of PD pathogenesis remain unclear.”
Background
(Neuro)Psychological Interventions for Non-Motor Symptoms in the Treatment of Patients with Parkinson’s Disease: a Systematic Umbrella Review
Kampling, H., Brendel, L. K., & Mittag, O. (2019) · Neuropsychology Review · doi:10.1007/s11065-019-09409-4 · Cited by 21
Embryonic Zebrafish as a Model for Investigating the Interaction between Environmental Pollutants and Neurodegenerative Disorders
Yin, J., & Horzmann, K. A. (2024) · Biomedicines · doi:10.3390/biomedicines12071559 · Cited by 20
Apoptotic Mediators are Upregulated in the Skeletal Muscle of Chronic/Progressive Mouse Model of Parkinson's Disease
Erekat, N. S. (2015) · The Anatomical Record · doi:10.1002/ar.23124 · Cited by 20
Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial
Pérez‐López, C., Hernández‐Vara, J., Caballol, N. S., Bayés, À., Buongiorno, M., López-Ariztegui, N., Gironell, A., López‐Sánchez, J. D., Martínez‐Castrillo, J. C., Álvarez, S. M., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.835249 · Cited by 21
“It is planned for the trial to include 164 patients who meet all the following inclusion criteria: (1) idiopathic PD according to the clinical criteria of the Brain Bank of the United Kingdom (22), (2) moderate to severe disease (Hoehn & Yahr stage ≥2 in the OFF state) (23), and (3) presence of motor fluctuations, wit…”
BackgroundMethod
An Update on the Application of Nano Phytomedicine as an Emerging Therapeutic Tool for Neurodegenerative Diseases
Hussain, M. S., Chaturvedi, V., Goyal, S., Singh, S., & Mir, R. H. (2023) · Current Bioactive Compounds · doi:10.2174/0115734072258656231013085318 · Cited by 20
Neuroprotective Potential of Melatonin: Evaluating Therapeutic Efficacy in Alzheimer's and Parkinson's Diseases
Talbot, N. C., Luther, P. M., Spillers, N. J., Ragland, A. R., Kidder, E. J., Kelkar, R. A., Varrassi, G., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. D. (2023) · Cureus · doi:10.7759/cureus.50948 · Cited by 21
“PD affects about 0.5-1.0% of those aged 65-69 and 1.0-3.0% of those aged 80 or older [29,34,35].”
BackgroundInfluential
Unchanged safety outcomes in deep brain stimulation surgery for Parkinson disease despite a decentralization of care
McGovern, R. A., Sheehy, J. P., Zacharia, B. E., Chan, A. K.-H., Ford, B., & McKhann, G. M. (2013) · Journal of neurosurgery · doi:10.3171/2013.8.jns13475 · Cited by 20
Role of estrogen and levodopa in 1-methyl-4-pheny-l-1, 2, 3, 6-tetrahydropyridine (mptp)-induced cognitive deficit in Parkinsonian ovariectomized mice model: A comparative study
Yadav, S. K., Pandey, S., & Singh, B. (2017) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2017.07.002 · Cited by 20
Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinson’s disease
Deng, X., Xiao, B., Li, H., Lo, Y., Chew, L.-M., Prakash, K. M., & Tan, E. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7855-8 · Cited by 20
“Parkinson’s disease (PD) is a common neurodegenerative disorder that affects 1 % of the population worldwide after the age of 65 years [1].”
Background
Psychosis in parkinson's disease: Diagnosis and treatment
Doraiswamy, M. P., Martin, W., Metz, A. L., & DeVeaugh-Geiss, J. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00114-b · Cited by 20
Ethics of fetal tissue transplantation.
Sanders, L., Giudice, L. C., & Raffin, T. A. (1993) · PubMed Central · Cited by 20
Comparison of Environmental and Genetic Factors for Parkinson’s Disease between Chinese and Caucasians
Chan, D. K. Y., Cordato, D. J., Bui, T., Mellick, G. D., & Woo, J. (2004) · Neuroepidemiology · doi:10.1159/000073970 · Cited by 20
Targeting tau in Alzheimer’s and beyond: Insights into pathology and therapeutic strategies
Singh, S., Khan, S., Shahid, M., Sardar, M., Hassan, M. I., & Islam, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102639 · Cited by 19
Epidemiology of Parkinson’s Disease in Chile
Felipe Vial, U., Delgado, I., Idiaquez, J. F., Canals, F., & Chaná‐Cuevas, P. (2021) · Neuroepidemiology · doi:10.1159/000517750 · Cited by 19
Liquid-liquid phase separation regulates alpha-synuclein aggregate and mitophagy in Parkinson’s disease
Hou, K., Liu, T., Li, J., Xian, M., Sun, L., & Wei, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1250532 · Cited by 22
“PD occurs mainly in older age groups, with a prevalence of about 0.5–1% in people aged 65–69 years, rising to 1–3% in people aged 80 years and older, and with a higher prevalence in men than in women (Tanner and Goldman, 1996; GBD 2016 Parkinson’s Disease Collaborators, 2018).”
Influential
Validity and Utility of a LRRK2 G2019S Mutation Test for the Diagnosis of Parkinson's Disease
Kay, D. M., Bird, T. D., Zabetian, C. P., Factor, S. A., Samii, A., Higgins, D. S., Nutt, J. G., Roberts, J. W., Griffith, A., Leis, B. C., et al. (2006) · Genetic Testing · doi:10.1089/gte.2006.10.221 · Cited by 19
Use of antiparkinsonian drugs in Denmark: Results from a nationwide pharmacoepidemiological study
Brandt‐Christensen, M., Kvist, K., Nilsson, F. M., Andersen, P. K., & Kessing, L. V. (2006) · Movement Disorders · doi:10.1002/mds.20907 · Cited by 19
Maintaining the Square: How Older Adults with Parkinson's Disease Sustain Quality in Their Lives
Whitney, C. M. (2004) · Journal of Gerontological Nursing · doi:10.3928/0098-9134-20040101-07 · Cited by 19
A Novel 6-Item Screening Questionnaire for Parkinsonism: Validation and Comparison Between Different Instruments
Fereshtehnejad, S., Shafieesabet, M., Rahmani, A., Farhadi, F., Hadizadeh, H., Shahidi, G. A., Delbari, A., & Lökk, J. (2014) · Neuroepidemiology · doi:10.1159/000368167 · Cited by 18
Stearic Acid Supplementation in High Protein to Carbohydrate (P:C) Ratio Diet Improves Physiological and Mitochondrial Functions of Drosophila melanogaster parkin Null Mutants
Bajracharya, R., Bustamante, S., & Ballard, J. W. O. (2017) · The Journals of Gerontology Series A · doi:10.1093/gerona/glx246 · Cited by 18
Interactions of Volatile Anesthetics with Neurodegenerative-Disease-Associated Proteins
Carnini, A., Eckenhoff, M. F., & Eckenhoff, R. G. (2006) · Anesthesiology Clinics of North America · doi:10.1016/j.atc.2006.02.002 · Cited by 18
“For example, it is fairly well established that certain pesticides contribute to Parkinson’s disease in workers and farmers so exposed [3].”
Background
Early intervention in Parkinson's disease: Epidemiologic considerations
Tanner, C. M. (1996) · Annals of Epidemiology · doi:10.1016/s1047-2797(96)00066-x · Cited by 18
Self-citation
Systematic review and meta-analysis of Sniffin Sticks Test performance in Parkinson’s disease patients in different countries
Trentin, S., de Oliveira, B. S. F., Borges, Y. F. F., & Rieder, C. R. D. M. (2021) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-021-06970-8 · Cited by 17
A comprehensive and updated review on the applications of vesicular drug delivery systems in treatment of brain disorders: A shelter against storms
Rajizadeh, M. A., Motamedy, S., Mir, Y., Akhgarandouz, F., Nematollahi, M. H., & Nezhadi, A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105011 · Cited by 17
Factors related to functional independence in females with Parkinson's disease: A systematic review
Roland, K. P., Jakobi, J. M., Powell, C., & Jones, G. R. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.05.009 · Cited by 17
Cell-based Therapeutic Approaches for Parkinson's Disease: Progress and Perspectives
Anisimov, S. V. (2009) · Reviews in the Neurosciences · doi:10.1515/revneuro.2009.20.5-6.347 · Cited by 17
α-Synuclein: Multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson’s disease
Zalon, A. J., Quiriconi, D. J., Pitcairn, C., & Mazzulli, J. R. (2024) · The Neuroscientist · doi:10.1177/10738584241232963 · Cited by 16
Auditory entrainment of motor responses in older adults with and without Parkinson’s disease: An MEG study
Buard, I., Dewispelaere, W. B., Teale, P. D., Rojas, D. C., Kronberg, E., Thaut, M. H., & Kluger, B. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134331 · Cited by 16
Circulating (Poly)phenol Metabolites: Neuroprotection in a 3D Cell Model of Parkinson's Disease
Carecho, R., Figueira, I., Terrasso, A. P., Godinho-Pereira, J., Sequeira, C. O., Pereira, S. A., Milenković, D., Leist, M., Brito, C., & dos Santos, C. N. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100959 · Cited by 18
microRNA as a new agent for regulating neuronal glutathione synthesis and metabolism
Kinoshita, C., Aoyama, K., & Nakaki, T. (2015) · AIMS molecular science · doi:10.3934/molsci.2015.2.124 · Cited by 16
A Prospective Treatment Option for Lysosomal Storage Diseases: CRISPR/Cas9 Gene Editing Technology for Mutation Correction in Induced Pluripotent Stem Cells
Christensen, C. L., & Choy, F. Y. M. (2017) · Diseases · doi:10.3390/diseases5010006 · Cited by 16
Mitochondrial dysfunction and oxidative stress in Parkinson’s disease: mechanisms, biomarkers, and therapeutic strategies
Ushakiran, P., Haria, J., Rani, R., & Singh, S. K. (2025) · Tissue Barriers · doi:10.1080/21688370.2025.2537991 · Cited by 15
Scales for Assessing Nonmotor Symptom Severity Changes in Parkinson's Disease Patients With Symptom Fluctuations
Buck, P. O., Trautman, H., & Clark, J. C. (2010) · International Journal of Neuroscience · doi:10.3109/00207454.2010.489725 · Cited by 15
Cerebral blood flow laterality derived from arterial spin labeling as a biomarker for assessing the disease severity of parkinson's disease
Yamashita, K., Hiwatashi, A., Togao, O., Kikuchi, K., Yamaguchi, H., Suzuki, Y., Kamei, R., Yamasaki, R., Kira, J., & Honda, H. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25489 · Cited by 15
A quality improvement initiative on the management of osteoporosis in older people with Parkinsonism
Singh, I., Fletcher, R., Scanlon, L., Tyler, M., & Aithal, S. (2016) · BMJ Quality Improvement Reports · doi:10.1136/bmjquality.u210921.w5756 · Cited by 15
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson’s Disease
Baek, J.-S., Tee, J. K., Pang, Y., Tan, E. Y., Lim, K. L., Ho, H. K., & Loo, S. C. J. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8491-0 · Cited by 15
RETRACTED ARTICLE: Testing alternatives: the use of adipose-derived mesenchymal stem cells to slow neurodegeneration in a rat model of Parkinson’s disease
Meligy, F. Y., Elgamal, D. A., Allah, E. S. H. A., Idriss, N. K., Ghandour, N., Bayoumy, E. M. R., Khalil, A. S. A., Fiky, M. M. E., & El-Khashab, M. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05018-9 · Cited by 15
Retracted
A Two-Stage Tremor Detection Algorithm for Wearable Inertial Sensors During Normal Daily Activities
McNames, J., Shah, V. V., Mancini, M., Curtze, C., El‐Gohary, M., Aboy, M., Carlson‐Kuhta, P., Nutt, J. G., & Horak, F. B. (2019) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2019.8857133 · Cited by 15
Neuropharmacology of Dopamine Receptors : Implications in Neuropsychiatric Diseases
Tarazi, F. I. (2001) · Sultan Qaboos University medical journal · doi:10.18295/2075-0528.2587 · Cited by 15
Ultrasonographic (TCS) and clinical findings in overlapping phenotype of essential tremor and Parkinson’s disease (ET-PD)
Laučkaitė, K., Rastenytė, D., Šurkienė, D., Vaidelytė, B., Dambrauskaitė, G., Sakalauskas, A., Vaitkus, A., & Gleiznienė, R. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-54 · Cited by 15
Impact of social functioning and vitality on preference for life in patients with Parkinson's disease
Morimoto, T., Shimbo, T., Orav, E. J., Matsui, K., Goto, M., Takemura, M., Hira, K., & Fukui, T. (2002) · Movement Disorders · doi:10.1002/mds.10323 · Cited by 16
Micronutrients and Risk of Parkinson’s Disease
Sherzai, A. Z., Tagliati, M., Park, K., Pezeshkian, S., & Sherzai, D. (2016) · Gerontology and Geriatric Medicine · doi:10.1177/2333721416644286 · Cited by 18
Clinical findings and genetic screening for copy number variation mutations in a cohort of South African patients with Parkinson’s disease
Mahne, A. C., Carr, J. A., Bardien, S., & Schutte, C. M. (2016) · South African Medical Journal · doi:10.7196/samj.2016.v106i6.10340 · Cited by 15
Verb naming fluency in hypokinetic and hyperkinetic movement disorders
Bayram, E., & Akbostancı, M. C. (2017) · Cortex · doi:10.1016/j.cortex.2017.06.014 · Cited by 15
Parkinson's Disease Research Education and Clinical Centers (PADRECC): Background and overview
Diaz, N., & Bronstein, J. M. (2005) · Neurorehabilitation · doi:10.3233/nre-2005-20302 · Cited by 15
“with age [12].”
In silico identification of potent inhibitors of alpha-synuclein aggregation and its in vivo evaluation using MPTP induced Parkinson mice model
Jayaraj, R. L., & Elangovan, N. (2014) · Biomedicine & Aging Pathology · doi:10.1016/j.biomag.2014.01.002 · Cited by 14
The Neuropsychology of Parkinson’s Disease
Demakis, G. J. (2007) · Disease-a-Month · doi:10.1016/j.disamonth.2007.04.005 · Cited by 14
Recent Progress of Imaging Agents for Parkinson’s Disease
Wu, X., Cai, H., Ge, R., Li, L., & Jia, Z. (2014) · Current Neuropharmacology · doi:10.2174/1570159x13666141204221238 · Cited by 14
Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson’s Disease
Huters, A. D., Stambuli, J. P., Klix, R. C., Matulenko, M. A., Chan, V. S., Simanis, J. A., Hill, D. R., Reddy, R. E., Towne, T. B., Bellettini, J. R., et al. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c00905 · Cited by 14
Whooping Cough and Parkinson's Disease
PEDRO-CUESTA, J. S. D., Guðmundsson, G., Abraira, V., Guðmundsson, G. S., Löve, A., Tulinius, H., VEIGA, J., N, J. A., & PETERSEN, I. J. (1996) · International Journal of Epidemiology · doi:10.1093/ije/25.6.1301 · Cited by 13

Authors: Tanner, C. M., & Goldman, S. M.
Affiliations: Parkinson's Institute and Clinical Center (US)
ORCID: Tanner, Caroline M.
Goldman, Samuel M.
Venue: Neurologic Clinics
Publisher: Elsevier BV
Published: 1996-05
Volume: 14
Issue: 2
Pages: 317-335
ISSN: 0733-8619 (ISSN-L)
DOI: 10.1016/s0733-8619(05)70259-0
PMC: PMC7173037
OpenAlex: W2084553926
Semantic Scholar: 722f96a983f226977773068a6a70c00979c0cbd5
Cited by: 640
References: 240
Citations by year: 2026: 9 · 2025: 10 · 2024: 17 · 2023: 29 · 2022: 23 · 2021: 26 · 2020: 14 · 2019: 24 · 2018: 35 · 2017: 36 · 2016: 28 · 2015: 26 · 2014: 32 · 2013: 28 · 2012: 19
FWCI: 11.14
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Neurologic Clinics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA094089)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, etiology, complex diseases, genetic risk factors, environmental risk factors, incidence, prevalence, levodopa, early markers, disease susceptibility, disease progression
MeSH terms: Aged, Consanguinity, Diet, Environmental Exposure, Female, Humans, Male, Middle Aged, Parkinson Disease, Risk Factors, Smoking, Global Health, Hazardous Substances, Incidence, Prevalence, Age Distribution, Sex Distribution, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks